Table 1.

Summary of intracerebral injections of mice

Strain	Inoculum	Time after injection (months)	Number of mice	Pathological findings	Induced pSer129/81A staining	Detection by multiple markersa
M20 (WT αS)	2 μl of PBS	1	4	1 of 4 mice shows rare puncta at the injection site	Yes	No
M20 (WT αS)	2 μl of PBS	2	2	No inclusions	No	No
M20 (WT αS)	2 μl of PBS	4	5	No inclusions	No	No
M20 (WT αS)	Δ71–82 αS (2 μl of 2 mg/ml)	1	4	3 of 4 mice show rare puncta in the cortex and at the injection site	Yes	No
M20 (WT αS)	Δ71–82 αS (2 μl of 2 mg/ml)	2	4	4 of 4 mice show sparse puncta in the cortex and at the injection site	Yes	No
M20 (WT αS)	Δ71–82 αS (2 μl of 2 mg/ml)	4	6	5 of 6 mice show moderate pathology spreading beyond the injection siteb	Yes	Yes
M20 (WT αS)	hfib αS (2 μl of 2 mg/ml)	1	4	4 of 4 mice show moderate pathology at the injection sitec	Yes	Yes
M20 (WT αS)	hfib αS (2 μl of 2 mg/ml)	2	4	4 of 4 mice show moderate pathology in the cortex and the injection sitec	Yes	Yes
M20 (WT αS)	hfib αS (2 μl of 2 mg/ml)	4	8	8 of 8 mice show abundant, widespread pathologyc	Yes	Yes
M83 (A53T αS)	hfib αS (2 μl of 2 mg/ml)	2	4	4 of 4 mice show abundant, widespread pathology	Yes	Yes

^aαS inclusion pathology confirmed with multiple αS antibodies and aggregate markers.

^bFor details of pathology spread, see Figure 3D.

^cFor details of pathology spread, see Figure 2A.